|
SH2D3C expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.901100E-03 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.785600E-04 |
| Normal-vs-Stage2 |
7.634700E-04 |
| Normal-vs-Stage3 |
9.442200E-01 |
| Normal-vs-Stage4 |
6.328000E-01 |
| Stage1-vs-Stage2 |
7.705600E-02 |
| Stage1-vs-Stage3 |
1.359900E-03 |
| Stage1-vs-Stage4 |
5.018300E-03 |
| Stage2-vs-Stage3 |
7.157400E-04 |
| Stage2-vs-Stage4 |
1.095010E-03 |
| Stage3-vs-Stage4 |
6.601000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.604400E-02 |
| Normal-vs-AfricanAmerican |
7.917200E-01 |
| Normal-vs-Asian |
1.846010E-02 |
| Caucasian-vs-AfricanAmerican |
5.612200E-01 |
| Caucasian-vs-Asian |
9.979500E-02 |
| AfricanAmerican-vs-Asian |
1.763800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.400030E-02 |
| Normal-vs-Female |
2.327900E-02 |
| Male-vs-Female |
3.926200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.403200E-03 |
| Normal-vs-Age(41-60Yrs) |
8.861900E-02 |
| Normal-vs-Age(61-80Yrs) |
1.550590E-01 |
| Normal-vs-Age(81-100Yrs) |
6.295800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.059380E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.205600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.794400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.496000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.159400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.178400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.66690000000092E-05 |
| Classical-VS-Follicular |
1.93569999999976E-05 |
| Classical-VS-Other |
4.028600E-01 |
| Classical-VS-Normal |
4.986400E-02 |
| Tall-VS-Follicular |
1.98490002212282E-10 |
| Tall-VS-Other |
3.371200E-01 |
| Tall-VS-Normal |
9.724500E-03 |
| Follicular-VS-Other |
2.180400E-02 |
| Follicular-VS-Normal |
9.14550000175041E-08 |
| Other-VS-Normal |
6.801800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.761500E-04 |
| Normal-vs-N1 |
6.080800E-01 |
| N0-vs-N1 |
4.711500E-02 |
|
|
